2018
DOI: 10.1007/s00198-018-4507-8
|View full text |Cite
|
Sign up to set email alerts
|

Anabolic agents: what is beyond osteoporosis?

Abstract: Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce new bone. Currently, two anabolic agents are available in the USA: recombinantly produced teriparatide (TPTD), which is the fully active (1-34) amino active sequence of human parathyroid hormone (PTH), and abalopara… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
29
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(29 citation statements)
references
References 82 publications
0
29
0
Order By: Relevance
“…Although the consideration of PTH or PTHrP in such other instances has merit, they are not discussed in this review in order to focus on fracture healing. In addition, they are covered elsewhere . Abstracts and the full text of the matched articles were collected.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Although the consideration of PTH or PTHrP in such other instances has merit, they are not discussed in this review in order to focus on fracture healing. In addition, they are covered elsewhere . Abstracts and the full text of the matched articles were collected.…”
Section: Methodsmentioning
confidence: 99%
“…In addition, they are covered elsewhere. (11)(12)(13)(14)(15) Abstracts and the full text of the matched articles were collected. References cited in the identified articles were also screened for inclusion.…”
Section: Methodsmentioning
confidence: 99%
“…There have already been several studies presenting the effects of teriparatide for bone formation, fusion, and defect healing. 8 10 11) …”
Section: Discussionmentioning
confidence: 99%
“…143 Such applications include but are not limited to osteoporosis, periodontal regeneration, jaw osteonecrosis, spine fusion, arthroplasty, and fracture healing. 144,145 Much of the rationale for these applications is based on the role of PTH in mineral and skeletal homeostasis as well as PTHrP in chondrocyte regulation within the developing and postnatal growth plate. 146 Intermittent administration of large PTH1-34 or PTH1-84 doses have increased trabecular bone mass in both animal models and osteoporotic patient populations.…”
Section: Growth Factor-based Therapymentioning
confidence: 99%